Sirolimus Rx

T-01

Rapamycin doses actually studied in humans (mg/kg visualizer)

Shows every sirolimus dose specified by the FDA label or administered in the human studies this site cites, by indication, converted between total mg and mg/kg for a user-entered body weight. Mouse doses appear in their native ppm-of-diet units with an explicit no-conversion note. It answers 'what have humans actually been given, and how does folklore dosing compare' without prescribing anything.

Shows every sirolimus dose specified by the FDA label or administered in the human studies this site cites, by indication, converted between total mg and mg/kg for a user-entered body weight. Mouse doses appear in their native ppm-of-diet units with an explicit no-conversion note. It answers 'what have humans actually been given, and how does folklore dosing compare' without prescribing anything.

Weight unit

Published figures scaled to 70 kg

Renal transplant, low-to-moderate risk (FDA-approved use)human0.03 mg/kg/day (fixed 2 mg/day, oral)

6 mg loading day 1, then 2 mg once daily Setting: Specialist care with trough monitoring.

Renal transplant, high immunologic risk (FDA-approved use)human0.1 mg/kg/day (fixed 5 mg/day, oral)

Up to 15 mg loading day 1, then 5 mg once daily Setting: Specialist care with trough monitoring.

Lymphangioleiomyomatosis (FDA-approved use; MILES trial)human0.03 mg/kg/day (fixed 2 mg/day, oral)

2 mg once daily, adjusted to trough 5-15 ng/mL Setting: Specialist care; trough-titrated.

Healthy adults 70-95, safety pilot (off-label research)human0.01 mg/kg/day (fixed 1 mg/day, oral)

1 mg once daily for 8 weeks Setting: Randomized placebo-controlled pilot (Kraig 2018).

Scaled mass = published mg/kg x your entered weight. Fixed-dose study rows run the same arithmetic in reverse: mg/kg = the published total dose / your weight. Scaling arithmetic does not transfer evidence between species; dose selection for humans is a clinician's call, not a calculation.

Worked example

Worked example: 70 kg adult, the label's 2 mg daily maintenance

Convert weight if needed: 154 lb x 0.45359237 = 69.9 kg (use 70 kg). mg/kg for the 2 mg daily row: 2 / 70 = 0.029 mg/kg per day. Weekly total for schedule comparison: 2 x 7 = 14 mg/week. Compare: PEARL's higher arm was 10 mg compounded weekly; with compounded bioavailability about 31% of commercial, that weekly exposure is roughly equivalent to about 3 mg of commercial product, well under the label's 14 mg/week maintenance exposure. The mouse rows stay in ppm. No step here converts them, because no valid step exists.

Step by step

  1. Enter body weight and unit.
  2. Read each studied row's mg/kg at your weight.
  3. Read the schedule column: daily rows show weekly totals for honest comparison with weekly regimens.
  4. Note the compound column on the everolimus row and the no-conversion note on the mouse row.

Every pack study-dose row, including weekly, other-rapalog, and mouse ppm rows the visualizer refuses to convert

#IndicationBasisAs studiedSetting
D1Renal transplant, low-to-moderate risk (FDA-approved use)fixed_mg6 mg loading day 1, then 2 mg once dailySpecialist care with trough monitoring
D2Renal transplant, high immunologic risk (FDA-approved use)fixed_mgUp to 15 mg loading day 1, then 5 mg once dailySpecialist care with trough monitoring
D3Lymphangioleiomyomatosis (FDA-approved use; MILES trial)fixed_mg2 mg once daily, adjusted to trough 5-15 ng/mLSpecialist care; trough-titrated
D4Healthy adults 70-95, safety pilot (off-label research)fixed_mg1 mg once daily for 8 weeksRandomized placebo-controlled pilot (Kraig 2018)
D5Healthy adults, longevity trial (off-label research; compounded)fixed_mg_weekly5 or 10 mg compounded, once weekly, 48 weeksPEARL RCT (AgelessRx); primary endpoint missed; compounded bioavailability about 31% of commercial
D6Real-world longevity users (observational blood-level cohorts)fixed_mg_weekly_rangeCommercial 2, 3, 6, or 8 mg weekly; compounded 5, 10, or 15 mg weeklySelf-administered; levels peak about day 2; large inter-individual variability
D7Elderly immune trials (DIFFERENT COMPOUND: everolimus, not sirolimus)different_compoundEverolimus 0.5 mg/day, 5 mg/week, or 20 mg/week (2014 trial arms)Labeled here because these arms are often misquoted as rapamycin doses
D8ITP mouse lifespan studies (the famous results)ppm_diet4.7, 14, or 42 ppm of diet, lifelong or from late lifeNO HUMAN EQUIVALENT: no validated conversion from mouse dietary ppm to a human mg dose exists, and this tool will not invent one

Frequently asked questions

Why does the mouse row refuse to convert?

Because the studies dosed mice in ppm of chow with exposure verified by mouse blood levels, and no validated method turns that into a human mg dose. Sites that print a converted number are inventing it.

Why is there an everolimus row in a rapamycin tool?

Because the 2014 elderly immune trial's doses (0.5 mg/day, 5 mg/week) are constantly quoted as rapamycin dosing. They are everolimus doses. The row exists so the misquote dies here.

Does any row here support a longevity dose?

No. The longevity rows document what trials gave and what users take; none of them produced outcome evidence, and the one RCT missed its primary endpoint.

Tools: educational calculators and references only.

Start provider review